Compare · TLRY vs VLON
TLRY vs VLON
Side-by-side comparison of Tilray Brands Inc. (TLRY) and Vallon Pharmaceuticals Inc. (VLON): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both TLRY and VLON operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- TLRY is the larger of the two at $2.44B, about 80.6x VLON ($30.3M).
- TLRY has hit the wire 12 times in the past 4 weeks while VLON has been quiet.
- TLRY has more recent analyst coverage (14 ratings vs 1 for VLON).
- Company
- Tilray Brands Inc.
- Vallon Pharmaceuticals Inc.
- Price
- $6.74-2.67%
- $12.00+2453.19%
- Market cap
- $2.44B
- $30.3M
- 1M return
- -3.23%
- -
- 1Y return
- +40.96%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2021
- News (4w)
- 12
- 0
- Recent ratings
- 14
- 1
Tilray Brands Inc.
Tilray, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates through five segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, Wellness Business, and Business Under Development. It provides medical and adult-use cannabis products; pharmaceutical and wellness products; beverage alcohol products; and hemp-based food and other wellness products. The company offers its products to retailers, wholesalers, patients, physicians, pharmacies, clinics, hospitals, governments, and researchers. It has operations in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company was formerly known as Aphria Inc. Tilray, Inc. was incorporated in 2018 and is based in New York, New York.
Vallon Pharmaceuticals Inc.
Vallon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of prescription drugs for central nervous system disorders. The company develops abuse-deterrent amphetamine immediate-release, an abuse-deterrent oral formulation of immediate-release dextroamphetamine for the treatment of attention-deficit/hyperactivity disorder and narcolepsy. It also develops ADMIR, an abuse deterrent formulation of Ritalin. Vallon Pharmaceuticals, Inc. was incorporated in 2018 and is based in Philadelphia, Pennsylvania.
Latest TLRY
- Tilray Brands Positioned for U.S. Expansion Amid Historic Cannabis Rescheduling
- BrewDog USA Doubles Down on Headliners and Ignites Next Wave of Innovation for Spring and Summer
- SEC Form 4 filed by Hopkinson David G.
- Tilray Brands Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B7 filed by Tilray Brands Inc.
- Tilray Brands Marks 4/20, Reaffirming Its Leadership in Cannabis and Commitment to Advancing Medical Care
- SEC Form 424B5 filed by Tilray Brands Inc.
- Tilray Brands Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits
- Tilray Brands Accelerates Next Phase of Global Growth and Market Leadership
- Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities
Latest VLON
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- SEC Form 424B4 filed by Vallon Pharmaceuticals Inc.
- SEC Form EFFECT filed by Vallon Pharmaceuticals Inc.
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form S-1/A filed by Vallon Pharmaceuticals Inc. (Amendment)
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits
- SEC Form 424B3 filed by Vallon Pharmaceuticals Inc.
- Vallon Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders